Show simple item record

dc.contributor.advisorBaran, Yusufen_US
dc.contributor.advisorSaydam, Gürayen_US
dc.contributor.authorKacı, Fatma Necmiye
dc.date.accessioned2015-05-22T07:25:57Z
dc.date.available2015-05-22T07:25:57Z
dc.date.issued2015
dc.identifier.citationKacı, F. N. (2015). Synergistic apoptotic effects of bortezomib and methylstat inhibitor on different multiple myeloma cell lines. Unpublished master's thesis, İzmir Institute of Technology, İzmir, Turkeyen_US
dc.identifier.urihttp://hdl.handle.net/11147/4309
dc.descriptionThesis (Master)--Izmir Institute of Technology, Molecular Biology and Genetics, Izmir, 2015en_US
dc.descriptionFull text release delayed at author's request until 2018.02.06en_US
dc.descriptionIncludes bibliographical references (leaves: 42-47)en_US
dc.descriptionText in English; Abstract: Turkish and Englishen_US
dc.descriptionx, 47 leavesen_US
dc.description.abstractMultiple myeloma is one of the common hematological malignancies that affects plasma cells. Bortezomib, proteasome inhibitor, is an anticancer agent used for the treatment of multiple myeloma while methylstat is a demethylase inhibitor having anticancer potential. In this study, we investigated antiproliferative and apoptotic effects of methylstat alone or in combination with bortezomib. We also examined the genes involved in methylstat induced apoptosis. Cytotoxic effects of bortezomib and methylstat on U266 and ARH77 cells were demonstrated by MTT cell proliferation assay. To understand the apoptotic effects of these agents, loss of mitochondrial membrane potential was investigated by JC-1 method while phosphatidylserine localization was investigated by Annexin V assay. Cell cycle analysis in response to Bortezomib and Methylstat alone or in their combination were measured by flow cytometry. Changes in expression profiles of 84 genes underlying apoptosis, cell cycle control, DNA damage repair, and invasion and metastasis in response to Methylstat were determined by PCR Array. Our results demonstrated that both bortezomib and methylstat have antiproliferative and aoptotic effects in a time and dose dependent manner. Combination of bortezomib and methylstat induced apoptosis significantly as compared to any agent alone. In conclusion, we suggest methylstat as candidate agent for the treatment of MM after in vivo analyses.en_US
dc.language.isoengen_US
dc.publisherIzmir Institute of Technologyen_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectMultiple myelomaen_US
dc.subjectCanceren_US
dc.subjectBortezomiben_US
dc.titleSynergistic apoptotic effects of bortezomib and methylstat inhibitor on different multiple myeloma cell linesen_US
dc.title.alternativeBortezomib ve metilstat inhibitörünün farklı multipl myeloma hücre hatları üzerindeki sinerjik apoptotik etkilerien_US
dc.typemasterThesisen_US
dc.contributor.authorIDTR223300en_US
dc.contributor.departmentIzmir Institute of Technology. Molecular Biology and Geneticsen_US
dc.relation.publicationcategoryTezen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record